Tough Day at the Office: Lupus, Sarcoidosis, and a Side of Morphea
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr.
Adam Friedman, professor and chair of dermatology at GW School of Medicine and Health Sciences. Watch as Dr. Friedman shares basic principles to managing three distinct diseases – cutaneous lupus, sarcoidosis and linear morphea. Learn why you need to do a good review of organ systems and be prepared to phone a friend (or more) across the aisle in medicine. Find out Dr. Friedman’s mantra for treating these diseases, and why he says smoking cessation is important.
Dr. Adam Friedman lectured on this and other topics at the recent DERM2022 NP/PA CME conference held July 28-31, 2022.
Further Reading
If you want to read more about lupus, sarcoidosis and morphea, check out the following articles published in the Journal of Drugs in Dermatology:
A Retrospective Study of Calcinosis Cutis in Patients With Systemic Lupus Erythematosus
ABSTRACT
Calcinosis cutis (CC) is a very rare and poorly characterized finding in systemic lupus erythematosus (SLE).1 In this retrospective study, we present our experience of 10 individuals with SLE who developed CC, describing the epidemiology, diagnosis, and clinical characteristics of this rare entity.
Recalcitrant Diffuse Cutaneous Sarcoidosis With Perianal Involvement Responding to Adalimumab
ABSTRACT
Recalcitrant cutaneous sarcoidosis with perianal involvement is rare. To our knowledge we present the first documented case of cutaneous sarcoidosis with perianal involvement successfully treated with adalimumab.
ABSTRACT
Bullous morphea is rare clinical variant of localized scleroderma characterized by the formation of bullae on sclerotic morphea plaques. Severe disease may be highly disabling and greatly impair quality of life. Current treatment strategies are based on anecdotal reports of clinical experience and include topical corticosteroids, methotrexate and phototherapy. Herein, we describe the case of a 56-year-old woman with progressive bullous sclerotic lesions who was successfully treated with mycophenolate mofetil after treatment failure with psoralen plus ultraviolet A therapy, ultraviolet A1 phototherapy, and methotrexate. Treatment with mycophenolate mofetil halted disease progression after 8 weeks. No major adverse effects were recorded in a 3-year follow-up with continuous treatment. This case suggests mycophenolate mofetil may be considered as an alternative for the treatment of resistant bullous morphea lesions.
